Q1 2021 Genmab A/S Earnings Call Transcript
So hello, and welcome to the Genmab Conference Call to discuss the company's financial results for the period ended March 31, 2021. With me today to present these results is our CFO, Anthony Pagano.
Let's move to Slide 2. As already said, we will be making forward-looking statements. So please keep that in mind as we go through this call. Let's move to Slide 3. Genmab has an innovation-based culture and collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under these strategic collaborations, and this slide acknowledges those relationships.
Let's move to Slide 4. Through our 22-year history, we've had a laser-sharp focus on harnessing the power of human antibodies to develop differentiated cancer therapeutics. This slide provides a review of what is behind that focus. Our core purpose, which guides our work, our extremely successful strategy and our ambitious vision for the company. Genmab's evolution into a fully integrated biotechnology power house continued with the events of the first
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |